- Home
- PASG vs DARE Comparison
PASG vs DARE Comparison
Compare PASG & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- DARE
- Stock Information
- Founded
- PASG 2017
- DARE 2015
- Country
- PASG United States
- DARE United States
- Employees
- PASG N/A
- DARE N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- DARE Health Care
- Exchange
- PASG Nasdaq
- DARE Nasdaq
- Market Cap
- PASG 27.6M
- DARE 24.0M
- IPO Year
- PASG 2020
- DARE N/A
- Fundamental
- Price
- PASG $8.24
- DARE $1.74
- Analyst Decision
- PASG Strong Buy
- DARE Strong Buy
- Analyst Count
- PASG 4
- DARE 2
- Target Price
- PASG $34.50
- DARE $10.00
- AVG Volume (30 Days)
- PASG 41.6K
- DARE 108.0K
- Earning Date
- PASG 11-10-2025
- DARE 11-13-2025
- Dividend Yield
- PASG N/A
- DARE N/A
- EPS Growth
- PASG N/A
- DARE N/A
- EPS
- PASG N/A
- DARE N/A
- Revenue
- PASG N/A
- DARE N/A
- Revenue This Year
- PASG N/A
- DARE $5,401.89
- Revenue Next Year
- PASG N/A
- DARE $6,257.18
- P/E Ratio
- PASG N/A
- DARE N/A
- Revenue Growth
- PASG N/A
- DARE N/A
- 52 Week Low
- PASG $5.12
- DARE $1.61
- 52 Week High
- PASG $26.60
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- PASG 53.96
- DARE 42.59
- Support Level
- PASG $7.13
- DARE $1.61
- Resistance Level
- PASG $9.24
- DARE $1.84
- Average True Range (ATR)
- PASG 0.89
- DARE 0.12
- MACD
- PASG 0.03
- DARE -0.01
- Stochastic Oscillator
- PASG 57.09
- DARE 42.50
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.